Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
A University of Cincinnati researcher is working on a new light therapy that uses ultraviolet light to activate light-sensitive drugs, selectively targeting cancer cells while sparing healthy stem cells. This approach has the potential to be more effective and safer than current treatments.
A study in Germany shows that cancer patients face substantial financial impacts, including income loss and material hardship, with adverse psychological effects. The survey of 247 patients revealed that 80.6% faced higher out-of-pocket costs and 37.2% experienced significant income loss.
Researchers at USC and the Los Angeles Cancer Surveillance Program found that 15- to 39-year-olds have the best survival rate among any age group for many years. The analysis adjusted for Kaposi's sarcoma and lymphomas, which were linked to the HIV/AIDS epidemic in the US.
A clinical trial at UC San Diego Health is testing personalized vaccines that use a patient's unique cancer mutations to stimulate an immune response. The vaccine, combined with an FDA-approved checkpoint inhibitor, aims to unleash the full potential of T cells activated by the vaccine.
Researchers have developed a laboratory model that accurately evaluates MCL-1 inhibitors, enabling the identification of right patients for these drugs. The model predicts how cancer patients will respond to the drug in the clinic, allowing for effective treatment and potential breakthroughs in cancer therapy.
Two new clinical trials are underway at Cummings Veterinary Medical Center at Tufts University to study deadly cancers in dogs. These studies focus on osteosarcoma and solid tumors, and may provide valuable information for human cancer treatments.
Researchers have revealed the structure of immune protein IgM, showing it to be an incomplete hexagon. This discovery has significant implications for developing effective medicines for various diseases, including cancer and neurological disorders. The structural connection between IgM and AIM proteins suggests that drugs targeting AIM...
Three leading researchers, Ian Smith, Ann Partridge, and Zena Werb, receive top honors for their groundbreaking work on breast cancer treatment and research. Their contributions have propelled advances in breast cancer science and medicine, saving countless lives from the disease.
A study of over 6,000 patients with advanced cancer treated in community settings shows that nearly a quarter received targeted treatment based on DNA mutations. This achievement marks a significant shift towards precision medicine, allowing more patients to benefit from innovative therapies.
A commonly-used anti-psychotic drug has shown promise in treating aggressive triple negative breast cancer by inhibiting the growth and spread of cancer cells. The study found that up to 90% of cancer cells died following treatment with Pimozide, reducing tumour size and metastases.
Researchers at Case Western Reserve University have identified a previously uncharacterized structure within the human estrogen receptor that could serve as a valuable new drug target. By disrupting this interface, drugs may be able to inhibit receptor function and prevent metastasis.
A recent study found that palbociclib, a breast cancer drug, can effectively treat acute myeloid leukaemia (AML) with reduced toxicity compared to current chemotherapy. This breakthrough could lead to improved survival rates for patients with the serious condition.
A study published in Nature identified a tumor cell population responsible for resistance to therapy and tumor relapse in basal cell carcinoma. The researchers found that vismodegib promotes the differentiation of tumor cells, leading to their elimination, but also reveals a dormant population of tumor cells with active Wnt signaling.
Patients with AFib and a history of cancer are more likely to experience suboptimal antithrombotic care, leading to increased risk of stroke. Cardiology providers play a crucial role in improving outcomes for these patients, according to a study published in the Journal of the American College of Cardiology.
A new mouse study builds on human findings that link chemotherapy and the APOE4 gene variant to cognitive problems. The research, published in Neurotoxicity Research, reveals that APOE4 works with doxorubicin to cause significant brain changes and impair learning.
Sanjay Awasthi's research blocks stress-responsive protein Rlip to defeat deleterious effects of p53 loss, a common genetic defect in breast cancers. This discovery could lead to effective new medications for cancer, diabetes, and other health issues.
Scientists have found an old antibiotic that selectively kills cells producing high levels of ALDH1 in melanoma tumors. The therapy shows promise for complementing existing treatments and may offer a new approach to targeting drug resistance.
Researchers identified over 500 DNA sites requiring ATR enzyme to prevent breakage during replication. The findings suggest ATR inhibitors may enhance treatment efficacy for various cancers by targeting repetitive DNA sequences.
Researchers at The Wistar Institute developed synthetic DNA-encoded monoclonal antibodies targeting CTLA-4, achieving antitumor activity comparable to traditional monoclonals. The approach stimulates robust CD8+ T-cell infiltration and tumor clearance in mouse models.
Researchers have discovered a potential treatment for prostate cancer using riluzole, a drug approved for ALS treatment. The study found that riluzole promotes the degradation of androgen receptors, which drives prostate cancer growth.
Researchers at Stevens Institute of Technology have designed a novel molecule that uses a unique mechanism to halt or destroy breast cancer tumors. The molecule, developed by Abhishek Sharma, could potentially add to the arsenal of drugs targeting estrogen receptors in breast cancer therapy.
A researcher at UCF College of Medicine has discovered a way to make immunotherapy viable for thousands by using the body's own natural killer (NK) cells in a new way. Activated NK cells can change the cellular makeup of tumors, allowing the immune system to attack cancer more effectively.
The Cell Model Passports hub provides a central platform for accessing high-quality cancer cell models and genomic data. This will streamline the process of finding relevant models for research, enabling scientists to accelerate cancer research and develop new treatments.
Researchers found that deep space bombardment can significantly damage gastrointestinal tissue, leading to long-term functional alterations and high risk of tumor development. The study's findings raise concerns about the health of astronauts on long voyages, such as Mars.
The new system can produce different proteins in a fully automated, hands-free manner and is of comparable quality to commercially available versions. It enables flexible switching between products as they are needed, making it useful for producing rare disease treatments.
A McMaster University-led review of 52 articles found no significant association between progression-free survival and health-related quality of life in cancer patients. The study suggests that clinical trials should measure health-related quality of life directly to ensure patients are receiving effective treatments.
A new study from George Washington University Cancer Center found that nanoparticle-encapsulated doxorubicin is promising in treating triple-negative breast cancer. The smallest nanoparticles with slowest release of medication showed increased cell kill in resistant cancer cells, offering potential strategies to overcome drug resistance.
Moffitt researchers used a new technique to identify a previously unknown mechanism of midostaurin in lung cancer. Combining functional proteomics with deep network analysis led to the discovery of TBK1, PDPK1, and AURKA as protein targets for midostaurin, resulting in a more effective combination therapy.
Loyola will produce a more purified CAR-T cell product potentially reducing toxicities and costs. The Leukemia Research Foundation is supporting the research with a $250,000 grant.
Researchers at UCI will develop a new class of cancer-killing immunotherapeutics targeting abnormal glycans, which are nearly universal in cancer but limited in normal tissue. The goal is to broaden the types of cancers sensitive to immunotherapy and treat highly diverse types of cancer.
A Phase III clinical trial is enrolling men with metastatic Stage 4 prostate cancer to compare standard systemic therapy with or without surgery or radiation therapy. The goal is to delay disease progression and improve survival.
Researchers at the University of Liverpool discovered a lung cancer drug that can degrade 'zombie' proteins linked to leukemia. The study highlights the potential for repurposing drugs to target cancer therapies, particularly in acute myeloid leukaemia and acute lymphoblastic leukaemia.
A new drug called Metavert has shown promising results in blocking pancreatic cancer growth in laboratory mice. The study also found that Metavert may prevent patients from developing resistance to currently used chemotherapies.
Researchers developed a theranostic complex that targets tumor cells with two toxic modules, showing high therapeutic efficacy and imaging contrast. The complex uses yttrium-90-doped upconversion nanoparticles and targeted toxin to inhibit tumor growth and reduce drug resistance.
Scientists at Boston Children's Hospital have identified a potential new treatment for adenoid cystic carcinoma by targeting the MYB gene in zebrafish. The study found that retinoic acid derivatives effectively shut off the MYB gene, slowing tumor growth and validating its efficacy in human cells.
Researchers developed a handheld, portable device that can detect Kaposi sarcoma-associated herpesvirus (KSHV) with 94% accuracy in resource-limited settings. The Tiny Isothermal Nucleic acid quantification sYstem (TINY) generates results in under 2.5 hours, enabling early detection and better outcomes.
A new AI program can analyze lung tumor images to specify cancer types and identify genetic changes, offering a potential solution for faster diagnosis and treatment. The tool achieved high accuracy rates in distinguishing between adenocarcinoma and squamous cell carcinoma, as well as identifying altered genes linked to lung cancer.
A landmark study of over 19,000 participants aged 70+ found that taking low-dose aspirin daily does not prolong life free of disability or significantly reduce the risk of heart attacks and strokes. The study also showed an increased risk of serious bleeding among aspirin-takers.
A new method developed by University of Copenhagen researchers, His-tag acylation, allows for precise targeting of proteins, reducing the risk of side effects. The approach enables the creation of tailored pharmaceuticals with enhanced characteristics, such as tracking proteins' path through cells.
A recent study published in Journal of Internal Medicine found that adhering to an anti-inflammatory diet was associated with lower risks of dying from any cause, cardiovascular causes, and cancer. Participants who closely followed the diet had an 18% lower risk of all-cause mortality compared to those who followed it to a lesser degree.
An analysis of UK newspaper reporting on the NHS Cancer Drugs Fund found mostly positive but uncritical stories, potentially misleading the public about the fund's benefits. The study suggests that media coverage contributed to a strong perception that expensive new medicines are the best way to help cancer patients.
A study found that Medicaid expansion under the ACA did not increase access to complex surgeries at high-volume hospitals among ethnic/racial minorities and low-income populations. Despite overall increased surgical care access, disparities in complex surgery utilization persisted.
A study published in PLOS Pathogens identified three new molecular drug targets for the treatment of primary amebic meningoencephalitis. The researchers found that certain cancer drugs, such as tamoxifen and Prozac, are effective against the brain-eating amoeba Naegleria fowleri.
Researchers found that while severe reactions can occur, the risks are low compared to common cancer treatments. The study identified a peak timing for fatal toxicities within 15-40 days after treatment initiation, depending on the type of immune checkpoint inhibitor.
Researchers and regulators have conducted an expedited analysis of recalled blood pressure drugs, finding no association between use of potentially contaminated products and increased short-term cancer risk. However, a slightly increased risk of colorectal and uterine cancers was found in patients exposed to the impurity NDMA.
A new study by UCSF researchers reveals that nearly one in seven older veterans with hypertension are discharged with increased blood pressure medications despite having well-controlled blood pressure prior to their hospital stay. The study suggests a potential risk of medication harm due to overtreatment, particularly among older adults.
A DNA-based analysis can predict likelihood of disease recurrence in MDS patients after a stem cell transplant, helping doctors guide treatment decisions. The test identifies mutations before and after transplantation to detect residual cancer cells.
Researchers found that EVL protein helps contain cancer cells within the original tumor site by regulating actin cytoskeleton, which may lead to combination treatments for patients with ER-positive tumors.
Researchers at University of Houston develop synthetic compound that inhibits two major pathways of pancreatic cancer. The drug, MA242, targets NFAT1 and MDM2, reducing tumor growth and progression.
A new study published in JAMA found that immediately reducing nicotine in cigarettes leads to more rapid positive public health effects, including decreased exposure to toxic chemicals and increased smoke-free days. However, smokers may experience more severe withdrawal symptoms during the transition.
The new study reveals that different KRAS mutations have distinct effects on the KRAS protein's molecular-level function. The findings enhance understanding of cancer-causing mutations and may lead to the development of targeted drug therapies.
A widely used drug has been identified as a contributor to skin cancer development, with researchers calling for enhanced sun protection advice. The study, published in Nature Communications, found a strong association between azathioprine use and a specific mutational signature in cutaneous squamous cell carcinoma.
A new study analyzed data from two UK and US centers to find that patients with advanced lung cancer often receive multiple medications that may not be beneficial. On average, these patients were prescribed 1.9-2.6 preventative medications at admission and discharge. The authors suggest developing an intervention to reduce inappropriat...
The 2018 Dr. Paul Janssen Award Symposium will highlight recent advances in immuno-oncology and innovative strategies for optimizing cancer treatment. James P. Allison, PhD, will receive the award for his leading role in developing ipilimumab, a first immune checkpoint inhibitor approved by the FDA.
A clinical study using the CURATE.AI platform successfully treated a patient with metastatic castration-resistant prostate cancer, completely halting disease progression. The AI platform continuously optimised novel drug combination dosages to achieve a durable response, allowing the patient to resume an active lifestyle.
A researcher has linked the mysterious illness affecting American and Canadian diplomats in Cuba and China to radiofrequency/microwave radiation. The study's findings may aid in treating affected individuals and shed light on a larger population of people experiencing similar health problems.
Researchers at Hong Kong Baptist University have developed a metal compound that inhibits the enzyme lysine-specific demethylase 5A (KDM5A) in TNBC tumours with less toxicity in mice. This discovery holds great promise for the development of targeted drugs for TNBC therapy, offering a new approach to treating this difficult form of bre...
Researchers identified six classes of genes that contribute to cancer resistance, including CDK4/6 inhibitors. Combining BET and CDK4/6 inhibitors completely stopped tumors from growing in preclinical experiments.
Researchers at Mount Sinai discovered that stromal cells in bladder cancer tumors prevent immune cells from attacking them, leading to low response rates with PD-1/PD-L1 inhibitors. The study identified genes linked to more aggressive cancers and found that tumors with these genes were less responsive to treatment.
A study by researchers at the University of Cincinnati found that cell metabolism significantly influences autophagy, a survival program used by some tumor cells to evade treatment. The findings suggest that manipulating this pathway could lead to better cancer treatments and outcomes.